SXTP
60 Degrees Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.92
−1.16%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1M | 1.0M | 607.6K | 253.6K | 223.2K |
| Cost of Revenue | 895.2K | 781.7K | 384.8K | 474.6K | 432.4K |
| Gross Profit | 215.8K | 223.8K | 222.8K | (221.0K) | (209.2K) |
| Operating Expenses | |||||
| R&D Expense | 2.3M | 2.1M | 5.0M | 691.8K | 525.6K |
| SG&A Expense | 6.6M | 6.3M | 5.0M | 4.2M | 1.3M |
| General & Admin Expense | 6.6M | 6.3M | 5.0M | 4.2M | 1.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (104.0K) | (403.6K) | (73.8K) | — | (288.0K) |
| Total Operating Expenses | 8.8M | 8.0M | 9.9M | 4.9M | 1.5M |
| Cost and Expenses | 9.7M | 8.8M | 10.3M | 5.4M | 2.0M |
| Operating Income (EBIT) | (8.6M) | (7.8M) | (9.7M) | (5.2M) | (1.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 7.6K | 7.8K | 7.9K | 2.3M | 4.0M |
| Net Interest Income | (7.6K) | (7.8K) | (7.9K) | (2.3M) | (4.0M) |
| Other Non-Op Income/Expense | 495.5K | 390.3K | 1.8M | 1.3M | (4.4M) |
| Non-Operating Income (excl Interest) | (503.1K) | (398.1K) | (1.8M) | (3.6M) | 437.5K |
| EBT (Pre-Tax Income) | (8.1M) | (7.4M) | (8.0M) | (3.8M) | (6.2M) |
| Income Tax Expense | (1.6K) | — | 250.00 | 250.00 | 500.00 |
| Bottom Line | |||||
| Net Income | (8.1M) | (7.4M) | (7.9M) | (3.8M) | (6.2M) |
| Earnings from Cont. Ops | (8.1M) | (7.4M) | (8.0M) | (3.8M) | (6.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.0M) | (7.4M) | (8.4M) | (3.8M) | (6.2M) |
| Per Share | |||||
| Basic EPS | ($6.05) | ($11.73) | ($74.20) | ($3.80) | ($4.28) |
| Diluted EPS | ($6.05) | ($11.73) | ($74.20) | ($3.80) | ($4.28) |
| Revenue Per Share | $0.42 | $1.50 | $5.35 | $10.47 | $9.22 |
| Shares | |||||
| Basic Shares Outstanding | 2.7M | 670211 | 113665 | 24208 | 24208 |
| Diluted Shares Outstanding | 2.7M | 670211 | 113665 | 24208 | 24208 |
| Profitability Metrics | |||||
| EBITDA | (8.1M) | (7.3M) | (7.9M) | (1.4M) | (2.1M) |
| D&A | 46.4K | 82.9K | 63.7K | 100.4K | 78.8K |
| EBIT | (8.1M) | (7.4M) | (7.9M) | (1.5M) | (2.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026